TG Therapeutics IncEquity-NMS: TGTX
Equity-NMS: TGTX
$13.99
+0.17
(8:00 pm IST)
Loading Chart
1D
1W
3M
1Y
5Y
Previous close
$13.99
Open
$13.99
Today’s high
$14.63
Today’s low
$13.85
52W low
$6.46
52W high
$35.67
1Y
-36.12%
5Y
12.29%
PE
163.38
EPS (TTM)
0.09
Shares O/S
154.42M
Market cap
2.16B
Insights
TGTX price is above its 200 day moving average
TGTX PE is in the highest 10% across all stocks. The market is valuing it as a growth stock on an earnings basis.
In beta. Send feedback here.
Compare with other stock
Price
1D
PE
Market cap
About TG Therapeutics Inc

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities. .


FAQs

Can I buy TG Therapeutics Inc shares in India?
How to buy TG Therapeutics Inc shares in India?
What is the share price of TG Therapeutics Inc?
What is the Market Capitalization of TG Therapeutics Inc?
What is the PE ratio of TG Therapeutics Inc?
Is TG Therapeutics Inc a good stock to buy?
In which sector / industry does TG Therapeutics Inc operate?